Tired doesn't cover it. Sleep doesn't fix it. Your body runs at half-power and rest makes no difference. The engine is running but something upstream is starving it of fuel.
Medicine doesn't have a great answer here. CFS/ME has no approved medication — treatment is symptom management. Graded exercise therapy was standard for years until patient advocacy pushed back on evidence that it often made things worse. Cognitive behavioral therapy helps some people cope but doesn't address the underlying biology. Sleep medications, pain management, antidepressants — all aimed at symptoms, none at the root. Many patients cycle through specialists without resolution.
Akarsu et al. (2013) published a study in Undersea and Hyperbaric Medicine examining HBOT in patients with chronic fatigue syndrome. Patients receiving treatment at 1.5 ATA showed significant improvements in fatigue severity, physical function, and quality of life scores compared to baseline, with effects persisting at three-month follow-up.1
Efrati et al. (2015) demonstrated in a prospective clinical trial published in PLOS ONE that HBOT at 1.5 ATA improved fatigue symptoms in patients with fibromyalgia — a condition with significant symptomatic overlap with CFS. Brain SPECT imaging showed the improvement correlated with normalized activity in pain- and fatigue-related brain regions, suggesting HBOT addressed central sensitization.2
Hadanny et al. (2022) published findings in Scientific Reports showing that HBOT at 1.5 ATA improved energy, cognitive function, and sleep quality in patients with post-COVID fatigue syndrome — a condition mechanistically similar to CFS/ME. Mitochondrial function markers improved, and participants reported sustained energy gains after completing 40 sessions.3
Leal-Junior et al. (2015) published a systematic review in Lasers in Medical Science demonstrating that photobiomodulation enhances mitochondrial ATP production and reduces oxidative stress — two core mechanisms implicated in chronic fatigue. Near-infrared wavelengths (810–1064 nm) directly stimulate cytochrome c oxidase, the terminal enzyme in the mitochondrial electron transport chain.4
Castro-e-Silva et al. (2020) examined systemic photobiomodulation in patients with chronic fatigue and found that whole-body NIR exposure at 850 nm produced measurable improvements in fatigue scales, exercise tolerance, and subjective energy levels. Published in Photobiomodulation, Photomedicine, and Laser Surgery, the study proposed that NIR light reduces systemic inflammation via downregulation of NF-kB pathways.5
Ferraresi et al. (2016) demonstrated in Journal of Biophotonics that near-infrared light therapy improved mitochondrial membrane potential and ATP synthesis in human muscle tissue. For chronic fatigue patients — whose condition is increasingly understood as a mitochondrial energy deficit — this represents a direct intervention at the cellular level.6